



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

19th May 2025
IOLCP/CGC/2025

National Stock Exchange of India Ltd.

Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051

Security Symbol: IOLCP

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai- 400 001

Security Code: 524164

Subject: Investor Presentation-Q4 FY2025.

Dear Sir,

Please find enclosed herewith the Investor Presentation on the Financial Results of the Company for the quarter and year ended 31st March 2025. This presentation is being submitted in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This presentation is also made available on the Company's website www.iolcp.com

Thanking you,

Yours faithfully,

for **IOL Chemicals and Pharmaceuticals Limited**

Abhay Raj Singh

Sr. Vice President & Company Secretary



IOL Chemicals and Pharmaceuticals Limited

Investor Presentation Q4 & FY25



Q4 & FY25 Performance



Commencement of New Paracetamol Unit (Unit-11)

- Commissioned Unit-11 for Paracetamol production at Barnala with an installed capacity of 10,800 MTPA on 24th March 2025
- The ₹155.51 crore investment, fully funded through internal accruals, enhances backward integration and scale.

Clopidogrel Capacity Expansion (Unit-5)

- Clopidogrel Bisulphate production capacity was increased from 180 MTPA to 240 MTPA at Unit-5.
- The ₹7.87 crore expansion was successfully completed on 24th March 2025, funded entirely through internal resources.

CEP Certification for Mesalazine (EDQM)

- EDQM granted CEP for Mesalazine on 16th January 2025, enabling exports to Europe and other CEP-accepting regions
- Mesalazine is a key API used in treating inflammatory bowel disease.

CEP Certification for Quetiapine Fumarate (EDQM)




- Received EDQM's CEP for Quetiapine Fumarate, an antipsychotic API widely used to treat various mental health disorders
- This paves the way for exports to Europe and CEP-compliant markets.




Ibuprofen Approval from CDE, China

- Secured regulatory approval for Ibuprofen from China's CDE, NMPA
- This milestone paves the way for exporting Ibuprofen to the Chinese market.

Q4 & FY25 Performance Highlights



	 ₹ 527.8 Cr Revenue from Operations	 ₹ 67.5 Cr EBITDA Margin 12.7%	 ₹ 31.6 Cr Profit After Tax Margin 5.9%
	₹ 2079.2 Cr Revenue from Operations	₹ 224.6 Cr EBITDA Margin 10.7%	₹ 101.0 Cr Profit After Tax Margin 4.8%



Standalone Profit & Loss Statement – Q4 & FY25



Particulars (in INR Cr.)	Q4 FY25	Q4 FY24	Y-o-Y	Q3 FY25	Q-o-Q	FY25	FY24
Revenue from Operations	527.8	503.9	4.7%	523.3	0.9%	2079.2	2,132.8
Other Income	4.5	7.5		4.1		22.4	30.1
Total Revenue	532.3	511.4	4.1%	527.4	0.9%	2101.6	2,162.9
Cost of Materials Consumed	347.6	349.3		336.0		1358.3	1,435.1
Purchase of Traded Goods	0.0	0.0		0.0		0.0	0.2
Changes in Inventories of Finished Goods and Work in Progress	-1.8	-26.8		18.1		33.5	-38.3
Employee Benefits Expense	52.4	49.7		52.4		216.6	201.0
Other Expenses	66.7	81.7		70.0		268.6	303.3
EBITDA	67.5	57.6	17.1%	50.9	32.4%	224.6	261.6
EBITDA %	12.7%	11.3%		9.7%		10.7%	12.1%
Depreciation and Amortisation Expense	18.5	16.4		18.7		71.9	62.9
EBIT	48.9	41.2	18.8%	32.3	51.6%	152.7	198.7
Finance Costs	4.0	3.4		4.5		14.8	16.1
PBT	44.9	37.8	18.9%	27.8	61.4%	137.9	182.6
Total Tax Expense*	13.3	9.6		7.3		36.9	47.2
Profit for the year	31.6	28.2	12.2%	20.6	53.9%	101.0	135.4
PAT %	5.9%	5.5%		3.9%		4.8%	6.3%
EPS	1.08	0.96		0.70		3.44	4.61

Standalone Balance Sheet – FY25



Particulars (in INR Cr.)	Mar 25	Mar 24
ASSETS		
Non-current assets		
(i) Property, plant and equipment	1,158.0	921.1
(ii) Right to Use Asset	0.0	0.0
(iii) Capital Work in progress	20.8	99.8
(iv) Other Intangible Assets	12.3	11.6
(v) Intangible Assets under development	1.1	1.0
(vi) Financial Assets		
- Investments	17.7	17.7
- Other Financial Assets	7.9	48.9
(vii) Other Non- Current Assets	12.8	24.4
Total Non-current assets	1,230.7	1,124.5
Current assets		
(i) Inventories	360.6	424.8
(ii) Financial Assets		
- Investments	3.3	2.9
- Trade receivables	513.7	471.2
- Cash and cash equivalents	78.0	7.5
- Bank balances other than above	129.9	135.1
- Other financial Assets	5.6	7.1
(iii) Current Assets (net)	0.3	6.8
(iv) Other Current Assets	59.6	64.0
Total Current Assets	1,151.1	1,119.5
TOTAL ASSETS	2,381.8	2,244.0

Particulars (in INR Cr.)	Mar 25	Mar 24
EQUITY AND LIABILITIES		
EQUITY		
(i) Equity share capital	58.7	58.7
(ii) Other equity	1,628.7	1,552.6
Total Equity	1,687.4	1,611.3
LIABILITIES		
Non-current liabilities		
(i) Financial Liabilities		
-Borrowings	0.0	0.0
-Lease Liabilities	0.0	0.0
(ii) Provisions	6.7	6.7
(iii) Deferred tax Liabilities (net)	77.8	66.1
(iv) Other Non-Current Liabilities	0.0	0.0
Total Non-Current Liabilities	84.5	72.9
Current liabilities		
(i) Financial liabilities		
-Borrowings	117.0	32.8
-Lease Liabilities	0.0	0.0
-Trade payables	427.6	469.2
-Other financial liabilities	46.2	37.6
(ii) Other Current Liabilities	17.1	16.9
(iii)Provisions	2.0	3.4
Total Current Liabilities	609.9	559.8
TOTAL EQUITY AND LIABILITIES	2,381.8	2,244.0

Standalone Cash Flow Statement– FY25




Particulars (in INR Cr.)	Mar 25	Mar 24
Cash Flow from Operating Activities		
Profit before Tax	137.9	182.6
Adjustment for Non-Operating Items	79.8	59.8
Operating Profit before Working Capital Changes	217.7	242.4
Changes in Working Capital	-20.7	90.1
Cash Generated from Operations	197.0	332.5
Less: Direct Taxes paid	-18.3	-42.0
Net Cash from Operating Activities	178.7	290.5
Cash Flow from Investing Activities	-154.2	-191.4
Cash Flow from Financing Activities	46.0	-92.5
Net increase/ (decrease) in Cash & Cash equivalent	70.5	6.6
Cash and cash equivalents at the beginning of the year	7.5	1.0
Effect of exchange rate changes on Cash & Cash Equivalent	0.0	0.0
Cash and cash equivalents at the end of the year	78.0	7.5



At a Glance

Journey So Far



Business Overview





Team size of **2900+** employees

2nd Largest producer of Iso Butyl Benzene (IBB) with ~30% Global share

Existing Facility: Spanning **180+ acres**
Expansion: Acquired **101 acres** on Chandigarh-Bathinda Highway for new site development

Zero Discharge Effluent Treatment Plant

Largest producer of Ibuprofen and the only company worldwide being backward integrated with ~30% Global share



Customer base across **80 countries**

DSIR-approved R&D facility with **50+ scientists** driving innovation across APIs and specialty chemicals

Over **20** products are commercialized with **8** products in pipeline

Major producer of Ethyl Acetate in India, producing **1,00,000 MTPA**

Net Debt to Equity Ratio **0.09**

Segment Overview- Pharmaceuticals



Largest global producer of Ibuprofen, with a ~30% market share and over 12,000 MT capacity

World's only company with full backward integration for all Ibuprofen intermediates and KSMs

Commenced a fully backward-integrated Unit-11 for Paracetamol manufacturing at Barnala, with an installed capacity of 10,800 MTPA

Filed 16 DMFs with USFDA and 19 CEPs with EDQM

CEP certification received for 16 APIs, enabling exports to Europe and other CEP-accepting countries

The state-of-the-art facility comprises 11 dedicated units focused on efficient, high-quality production across a diversified product range

Existing Product Portfolio

Ibuprofen

Ibuprofen Lysinate

Ibuprofen Sodium

Dex-Ibuprofen

Metformin HCL

Paracetamol

Clopidogrel

Pantoprazole Sodium

Fenofibrate

Levetiracetam

Lamotrigine

Losartan Potassium

Application across therapeutic areas



Anti – Inflammatory



Analgesic & Antipyretic



Anti - Diabetic



Anti - Convulsant



Anti - Platelet



Anti - Cholelithic




Anti- Cholesterol



Proton Pump Inhibitor

Strategic Shift Towards High-Value APIs



Segment Overview- Specialty Chemicals



2nd Largest global manufacturer of Iso Butyl Benzene (IBB) with a ~30% market share


Ethyl Acetate manufacturing capacity of over 1,00,000 MTPA

Backward integration for Ibuprofen and Paracetamol by producing Acetic Anhydride for captive and merchant sale


Asia's first continuous dual technology plant for MCA and Acetyl Chloride using green chemistry

REACH-certified for Ethyl Acetate, enabling exports to over 40 countries worldwide


Product Portfolio




Ethyl Acetate
1,00,000 TPA




Acetic Anhydride
25,000 TPA
(Major Input for Paracetamol)



Iso Butyl Benzene
12,000 TPA
(KSM for Ibuprofen)



Mono Chloro Acetic Acid
7,200 TPA
(Input for Ibuprofen)



Acetyl Chloride
5,200 TPA
(Input for Ibuprofen)

Addressing Diverse Segments



Pharmaceuticals



Flexible Packaging



Food Processing



Paints



Ink



Textiles



Pesticides




Chemical Intermediates

Pharmaceuticals- A Key Focus



Significant Increase in Pharma's Share of Segmental Revenue



Expanding the non-Ibuprofen Business			
	Installed Capacity	Regulatory Filings*	Therapeutic Area
Metformin Hydrochloride	7200 MTPA	USDMF, CEP & ANVISA GMP Approved, China DMF Active	Anti-Diabetic
Fenofibrate	Multiproduct Plant	USDMF, CEP & ANVISA GMP Approved, China DMF Active	Anti-Cholesterol
Paracetamol (Acetaminophen)	10,800 MTPA + 3600 MTPA	USDMF Under Review, CEP & ANVISA GMP Approved	Analgesic & Anti-pyretic
Levetiracetam	Multiproduct Plant	USDMF Under Review, CEP & ANVISA GMP Approved	Anti-Epileptic
Clopidogrel Bisulphate	240 MTPA	USDMF Filed, CEP & ANVISA GMP Approved, China DMF Under Review	Anti-Platelet
Pantoprazole Sodium	240 MTPA	USDMF Filed, CEP & ANVISA GMP Approved	Proton Pump Inhibitor
Lamotrigine	Multiproduct Plant	USDMF Filed, CEP & ANVISA GMP Approved	Anti-Convulsant
Losartan Potassium	Multiproduct Plant	USDMF Filed, CEP & ANVISA GMP Approved	Anti-Hypertensive

* Some of the listed products are also registered with other major regulatory authorities such as Korea, Taiwan and Russia

Manufacturing Facilities



API manufactured in batch manner and intermediates & Specialty chemicals in continuous product delivery manner based on DCS technology

Dedicated and multiproduct blocks involved in manufacturing of APIs

Facility is coupled with ISO class-8 HVAC system, PSA Nitrogen & Purified water along with 185 MTPH steam generation capacity with multiple boilers

Manufacturing facilities involves – Reactions, Filtration, Centrifugation, Drying, Blending & Sieving, Micronization operation

Four stage treatment zero discharge ETP, solvent recovery plants & EHS cell as a part of the facility

Dedicated decentralized utilities from -20 to 275 deg.C temp and dedicated co-generation plant of 17MW



From Lab to Launch: 20 Products Commercialised, 8 More in the Making — R&D at the Heart of Our Growth Story

3

Patents

16

DMF with USFDA

19

CEP with EDQM



A 120-member highly skilled team, including 50+ scientists, driving innovation across key focus areas



Working on generic molecules with latest equipment & techniques for process development



DSIR approved facility for research & development



In-house development of multi step products

Certifications & Accreditations



Approved USFDA facility since 2015, recertified in 2019	EUGMP Certification in 2013, 2017 & Recertification in 2020	Certificate of Suitability from EDQM	Certified Halal in accordance with Shariah Board Guidelines	Certificate of DMF Registration From MFDS Korea	ISO 9001:2015, 14001:2015 & 45001:2018
Certified Kosher	Certified WHO GMP (COPP)	Written confirmation from CDSCO	ISO 27001 & ISO 37001	REACH Certificate for ethyl acetate, enabling exports to 40+ countries worldwide.	GMP Certificate by Ministry of Industry and Trade of the Russian Federation
Ecovadis Bronze Medal for FY 2023-24	State Food and Drug Administration Manufacturing License, GMP	Social Accountability Standard	CDE of NMPA approval to export Metformin Hydrochloride to China Market in 2024	Approved ANVISA, Brazil GMP for 10 API Facilities	

Core Management Team



Varinder Gupta | (Managing Director)

Wide and rich experience of more than 38 years in the chemical & fertilizer industry and along with a comprehensive approach and strong Pharma API industry oversight has paved a way for innovation and excellence



Vikas Gupta | (Joint Managing Director)

Academically equipped with knowledge and possesses organizational capacity. He has worked in strategic department of the Company and played a main role in guiding Chemical and Pharmaceutical business of the company. He has been vital to the functioning of the company over the last 12 years



Abhiraj Gupta | (Executive Director)

Possesses requisite qualification and experience in the Company's business. He oversees the non-ibuprofen API and chemical business, R&D, regulatory, digital marketing, and strategic decisions. The non-ibuprofen API business is doing good and meeting its targets under his leadership.



Kushal Kumar Rana | (Director – Works)

Master's degree in Chemistry. Over 33 years in the pharmaceutical industry in companies like Morepen Laboratories, Chemiplast Industries. His expertise lies in looking after quality assurance, quality control & corporate regulatory affairs

Board of Directors



Rajender Mohan Malla
(Chairman and Independent Director)

- With four decades of experience held top and significant decision-making positions in Banks, Financial Institutions & NBFCs
- In his most recent executive roles, he was MD & CEO of PTC India Financial Services Limited (PFS), and prior to that CMD of IDBI



Sharad Tyagi
(Independent Director)

- Over 38 years of intrapreneurship in India and international markets in diverse industries including pharmaceuticals, OTC, automotive catalysts and specialty chemicals
- Most recently until December 2020, he was the Managing Director for Boehringer Ingelheim (BI) (2009-2020), India



Harpal Singh
(Independent Director)

- Over 37 year's experience of banking and financial services
- Most recently he was General Manager of Punjab National Bank and headed entire operations of bank in State of Punjab from 2010 to 2015



Ms Rajni Jha
(Independent Director)

- Ms. Rajni Jha is a accomplished Senior Pharmaceutical Regulatory, Quality, and Compliance professional with over 32 years of experience.
- An esteemed IIT Kanpur scholar with an M.Sc. in Synthetic Organic Chemistry from Kanpur University,
- Held leadership roles at top Indian pharmaceutical giants, including Ranbaxy, Torrent, and Glenmark Pharma.

Ensuring a Sustainable Tomorrow Through ESG Initiatives



100%	100%	0	81%	6.75%	5%
Water neutral	Zero Liquid Discharge (ZLD)	Frequency and severity rate	Power requirement met via renewable energy	Reduction in Combined Scope-01 + Scope 02 GHG Emission	Reduction in water consumption KL/ton of production in FY 2024-25

The background of the slide features a complex molecular structure composed of numerous spheres of varying sizes connected by thin rods, resembling a chemical or biological network. The color palette is a gradient of teal and green, with the top being a darker teal and the bottom transitioning into a lighter, more vibrant green. A central white horizontal band provides a clean space for the title text.


Industry Overview

API Industry- Overview




Global API Market Size (In USD Bn)

North America holds over 38% of the API market in 2024. Asia-Pacific—led by India and China posts the fastest growth at 8.7% CAGR.



Indian API Market Size (In USD Bn)

India is the 3rd largest API producer globally, contributing 8% to the market, with over 500 distinct APIs and 57% of WHO's prequalified APIs.



Growth Drivers for Indian API Market

Government Incentives

The Indian government launched a ₹6,940 crore PLI scheme in 2020, offering 6-year incentives for 41 critical APIs and KSMs.

Robust Regulatory Compliance

India leads globally with 752 USFDA-approved pharmaceutical manufacturing facilities as of 2024, the highest number outside the U.S.

Diversification of Global Supply Chains

COVID-19 exposed API supply risks. As a result, global pharma companies are diversifying their supply chains. With a strong manufacturing base and policy support, India is emerging as a key alternative to China for API sourcing

Increased R&D Investments

One of the key trends in India's pharmaceutical industry is the sharp rise in R&D investment. Companies are focusing on biosimilars, complex generics, and new chemical entities (NCEs) to drive innovation and strengthen global competitiveness.

Quality Manufacturing

India's lower labor and production costs make it a competitive global manufacturing hub, enabling the production of high-quality drugs and vaccines at economical rates compared to developed countries.


Rising Exports

Pharmaceutical exports from India were valued at USD 27.9 billion in FY 2023-24, showcasing a growth of 18.7% compared to the previous year. Indian pharma companies are expanding their footprint into emerging markets like Africa, Latin America, and Southeast Asia.


Specialty Chemicals Industry- Overview




Global Spec. Chem Market Size



Indian Spec. Chem Market Size



Region wise Spec. Chem Market Size Growth (FY25-30)



Key Highlights

- Asia Pacific led the specialty chemicals market in 2024 with a 41.05% share, fueled by growing demand from rapidly industrializing economies like China and India
- India is the second-largest market for specialty chemicals in the Asia-Pacific region, supported by strong demand from pharmaceuticals, agrochemicals, and personal care sectors
- India enjoys a strong cost advantage in specialty chemicals, with labor and power costs significantly lower than global averages. This has positioned the country as a key growth hub in the global specialty chemicals landscape.

India's Rising Role



China + 1 Strategy



Lower Manufacturing Cost



Favourable Government Policies



Export Growth Momentum
(15-20% Growth)



Skilled Manpower Availability



Proximity to Feedstock & Raw Material Availability


The background of the slide features a complex, three-dimensional molecular structure. It consists of numerous spherical atoms, some of which are transparent and show internal details like smaller spheres or patterns. These atoms are interconnected by thin, translucent rods representing chemical bonds. The overall color palette is a gradient of teal and green, with the molecular model appearing as a semi-transparent overlay. The central text is placed on a white horizontal band that cuts across the middle of the image.

Historical Performance


Historical Standalone Performance




Revenues




EBITDA & EBITDA %



Cash Profit After Tax




Segmental Revenue




■ Pharmaceuticals ■ Chemicals (net of intersegment)

Cash Flow from Operations



Capex Spent



Summary Statement of Standalone Profit and Loss



Particulars (in INR Cr.)	FY25	FY24	FY23	FY22
Revenue from Operations	2079.2	2,132.8	2,217.1	2,184.0
Other Income	22.4	30.1	25.6	32.0
Total Revenue	2101.6	2,162.9	2,242.7	2,216.1
Cost of Materials Consumed	1358.3	1,435.1	1,536.1	1,578.9
Purchase of Traded Goods	0.0	0.2	29.2	43.9
Changes in Inventories of Finished Goods and Work in Progress	33.5	-38.3	-18.2	-52.3
Employee Benefits Expense	216.6	201.0	168.2	141.3
Other Expenses	268.6	303.3	275.3	215.9
EBITDA	224.6	261.6	252.1	288.3
EBITDA %	10.7%	12.1%	11.2%	13.0%
Depreciation and Amortisation Expense	71.9	62.9	46.1	43.3
EBIT	152.7	198.7	206.0	245.1
Finance Costs	14.8	16.1	16.5	8.3
Exceptional Items	0.0	0.0	0.0	13.9
PBT	137.9	182.6	189.5	222.8
Total Tax Expense	36.9	47.2	49.5	57.2
Profit for the year	101.0	135.4	140.0	165.7
PAT %	4.8%	6.3%	6.2%	7.5%
EPS	3.44	4.61	4.77	5.64

Summary Statement of Standalone Balance Sheet



Particulars (in INR Cr.)	Mar 25	Mar 24	Mar 23	Mar 22
ASSETS				
Non-current assets				
(i) Property, plant and equipment	1,158.0	921.1	750.5	559.5
(ii) Right to Use Asset	0.0	0.0	0.1	1.0
(iii) Capital Work in progress	20.8	99.8	81.4	102.0
(iv) Other Intangible Assets	12.3	11.6	0.7	0.2
(v) Intangible Assets under development	1.1	1.0	8.2	3.2
(v) Financial Assets				
- Investments	17.7	17.7	17.7	0.1
- Other Financial Assets	7.9	48.9	233.9	205.3
(vi) Other Non- Current Assets	12.8	24.4	9.0	10.3
Total Non-current assets	1,230.7	1124.5	1101.5	881.6
Current assets				
(i) Inventories	360.6	424.8	325.5	409.9
(ii) Financial Assets				
- Investments	3.3	2.9	2.6	2.4
- Trade receivables	513.7	471.2	505.3	469.8
- Cash and cash equivalents	78.0	7.5	1.0	1.1
- Bank balances other than above	129.9	135.1	19.9	136.8
- Other financial Assets	5.6	7.1	3.8	23.0
(iii) Current Assets (net)	0.3	6.8	1.8	0.9
(iv) Other current assets	59.6	64.0	59.3	34.9
Total Current Assets	1,151.1	1119.5	919.1	1,078.7
TOTAL ASSETS	2,381.8	2244.0	2020.6	1,960.3

Particulars (in INR Cr.)	Mar 25	Mar 24	Mar 23	Mar 22
EQUITY AND LIABILITIES				
EQUITY				
(i) Equity share capital	58.7	58.7	58.7	58.7
(ii) Other equity	1,628.7	1552.6	1447.8	1331.6
Total Equity	1,687.4	1611.3	1506.6	1390.3
LIABILITIES				
Non-current liabilities				
(i) Financial Liabilities				
-Borrowings	0.0	0.0	0.0	0.0
-Lease Liabilities	0.0	0.0	0.0	0.2
(ii) Provisions	6.7	6.7	1.7	3.0
(iii) Deferred tax Liabilities (net)	77.8	66.1	56.4	53.2
(iv) Other non-current liabilities	0.0	0.0	0.1	0.3
Total Non-Current Liabilities	84.5	72.9	58.2	56.6
Current liabilities				
(i) Financial liabilities				
-Borrowings	117.0	32.8	79.6	42.8
-Lease Liabilities	0.0	0.0	0.2	1.0
-Trade payables	427.6	469.2	314.2	409.3
-Other financial liabilities	46.2	37.6	36.0	30.0
(ii) Other Current Liabilities	17.1	16.9	17.8	23.0
(iii) Provisions	2.0	3.4	8.1	7.3
Total Current Liabilities	609.9	559.8	455.9	513.4
TOTAL EQUITY AND LIABILITIES	2,381.8	2244.0	2020.6	1,960.3

Summary Statement of Standalone Cashflow




Particulars (in INR Cr.)	Mar 25	Mar 24	Mar 23	Mar 22
Cash Flow from Operating Activities				
Profit before Tax	137.9	182.6	189.5	222.8
Adjustment for Non-Operating Items	79.8	59.8	44.4	33.1
Operating Profit before Working Capital Changes	217.7	242.4	233.9	256.0
Changes in Working Capital	-20.7	90.1	-63.7	-102.3
Cash Generated from Operations	197.0	332.5	170.2	153.6
Less: Direct Taxes paid	-18.3	-42.0	-47.1	-62.6
Net Cash from Operating Activities	178.7	290.5	123.1	91.0
Cash Flow from Investing Activities	-154.2	-191.4	-119.2	-120.6
Cash Flow from Financing Activities	46.0	-92.5	-4.1	-1.6
Net increase/ (decrease) in Cash & Cash equivalent	70.5	6.6	-0.2	-31.2
Cash and cash equivalents at the beginning of the year	7.5	1.0	1.1	32.3
Effect of exchange rate changes on Cash & Cash Equivalent	0.0	0.0	0.0	0.0
Cash and cash equivalents at the end of the year	78.0	7.5	1.0	1.1




Backward Integration for Margin and Supply Chain Resilience

The company adopts a strategic approach of **backward integration** for key raw materials and intermediates once products achieve significant economies of scale, ensuring enhanced control over supply, cost efficiencies, and quality



Product Diversification Beyond Ibuprofen

The **non-Ibuprofen share** in the pharmaceuticals segment has increased from **18% to 34%** over the past five years, with a strong trajectory to further drive revenue and margin expansion over the next 2–3 years. Key products include Paracetamol, Metformin, Clopidogrel, Fenofibrate, and Pantoprazole



Export Contribution to Rise

With **15 DMFs** and **19 CEPs** filed, the company is well-placed for regulated market expansion and is awaiting USFDA inspection. Aiming to grow **export revenue share** to **~40%**



Scaling Through Land Acquisition

The company has **acquired 101 acres of land** alongside the **Chandigarh-Bathinda Highway**, near its existing facility, to support future expansion. It is in the process of securing clearances for industrial use, environmental compliance, and NHAI approvals

Thank You

COMPANY :



IOL Chemicals And Pharmaceuticals Limited

IOL Chemicals and Pharmaceuticals Ltd.

CIN : L24116PB1986PLC007030

Mr. Abhay Raj Singh - Sr. VP & Company Secretary

E-mail: investor@iolcp.com

www.iolcp.com

INVESTOR RELATIONS ADVISORS :



MUFG Intime India Private Limited

A part of MUFG Corporate Markets, a division of
MUFG Pension & Market Services

Ms. Prachi Ambre

+91 83559 85370

Prachi.ambre@in.mpms.mufig.com

Ms. Irfan Raeen

+91 97737 78669

irfan.raeen@in.mpms.mufig.com